Treatment of systemic-onset juvenile arthritis with canakinumab

Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Peitz, Joachim, Horneff, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045123/
https://www.ncbi.nlm.nih.gov/pubmed/27790042
http://dx.doi.org/10.2147/OARRR.S54215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045123/
https://www.ncbi.nlm.nih.gov/pubmed/27790042
http://dx.doi.org/10.2147/OARRR.S54215

Ejemplares similares